CompletedNCT02874690
Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD
Medication studyAges 8–21United States
Understand this study
Who was this study for?
Listed age limits: 8 years to 21 years.
- Listed locations
- Cincinnati, United StatesSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: February 19, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- EARLY Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 8 Years to 21 Years
- Official registry ID
- NCT02874690
- Official title
Show the full official title
Title: Eye Tracking as a Predictor of Methylphenidate Response in Autism With Co-morbid Attention Deficit Hyperactivity Disorder
Recruitment & locations
CompletedCincinnati
Questions about this study
Who is behind this study?
The study sponsor is Children's Hospital Medical Center, Cincinnati, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate and Placebo.
Who was this study for?
Listed age limits: 8 years to 21 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)